Adalimumab for severe psoriasis in Chinese children
Treatments studied
Part of Skin clinical trials.
This trial tests a medication called adalimumab (a biologic drug that reduces inflammation) in children with severe plaque psoriasis—a skin condition causing thick, scaly patches. The study aims to see if this injection can help children whose skin hasn't improved with creams, light therapy, or other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be 4–17 years old and weigh at least 15 kg (about 33 pounds)
- Child has been diagnosed with severe plaque psoriasis and has not responded well to creams, ointments, or light therapy
- Child and parent/guardian must be willing to sign consent forms and follow the study rules
- Child has not used other biologic medications in the past 12 weeks
- Child has not received certain light treatments (UVA or UVB) within the past 1–2 weeks
- Child has not received live vaccines in the past 3 months and will not receive them during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well and how safely a medicine called adalimumab works in children ages 6–17 with moderate-to-severe Crohn's disease (a condition causing inflammation in the digestive tract). Your child's doctor has already decided adalimumab is appropriate for them, and this study simply collects information about how they respond to it.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
This trial tests if adding a gluten-free, low-histamine anti-inflammatory diet, and in some cases physical therapy, helps children with mild-to-moderate plaque psoriasis. It aims to see if these lifestyle changes can improve skin symptoms when combined with usual treatment.
This study tests a new medicine called SHR-1314 for children aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if it safely reduces skin redness, scaling, and thickness.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
Hear when a new Severe Plaque Psoriasis in Chinese Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.